Thank you for your request for information that has been processed under reference number

Size: px
Start display at page:

Download "Thank you for your request for information that has been processed under reference number"

Transcription

1 Corporate Development Contact us: Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: Minicom: Follow us on Tuesday 6 th October 2015 Request under Freedom of Information Act 2000 Thank you for your request for information that has been processed under reference number Please provide the below information for the following conditions that can be treated through drug-delivery to home; Multiple Sclerosis () and Rheumatoid Arthritis (RA). 1. For each of the above conditions/therapies, please indicate how many patients are treated under the following circumstances: Total number of patients Condition Drug 2011/ / /14 In hospital** e.g. RA Drug 1 In hospital** e.g. RA Drug 2 In hospital** e.g. Drug 1 Hospitalprovided at- home Hospitalprovided at- home RA ADALIMUMAB RA CERTOLIZUMAB delivery by home RA ETANERCEPT

2 healthcare RA METHOTREXATE RA GOLIMUMAB BETA - 1a (AVONEX) BETA-1b (BETAFERON) BETA-1b (EXTAVIA) FINGOLIMOD GLATIRAMER ACETATE BETA - 1a (REBIF) Total **We are unable to provide you with this information, as we do not hold this data electronically. 2. For each of drug delivery services that you use, please indicate for the last three years: a. Name of provider - Evolution, Healthcare At Home, Boots, Alcura, Bupa, Medco, Pharmaxo b. Which home- appropriate conditions they treat Dermatology (Bupa, Healthcare at Home, Medco), (Bupa, Evolution, Healthcare at Home), RA (Alcura, Boots, Healthcare at Home, Medco), CF (Healthcare at Home), Crohns (Alcura, Healthcare at Home, Pharmaxo), Growth Hormone (Alcura, Healthcare at Home), HIV (Alcura Medco), Osteoporosis (Bupa), Parkinsons (Evolution), Renal (Healthcare at Home), Uvetitis (Healthcare at Home)

3 c. Which drugs are provided in this service current drugs ABACAVIR & LAMIVUDINE (KIVEXA) **HOMECARE** 600mg/300mg Tablets ABACAVIR **HOMECARE** 300 mg Tablets ACICLOVIR **HOMECARE** 400 mg Dispersible Tablets ADALIMUMAB ** HOMECARE DELIVERY ** 40 mg in 0.8mL Vial ADALIMUMAB **HOMECARE DELIVERY ONLY** 40 mg Pre-Filled Syringe ADALIMUMAB **HOMECARE DELIVERY ONLY** 40 mg Pre-Loaded Pen ADCAL-D3 **HOMECARE** Chewable Tablets APOMORPHINE **HOMECARE DELIVERY** 50 mg in 10mL Pre-Filled Syringe ATAZANAVIR **HOMECARE** 300 mg Capsules ATRIPLA **HOMECARE** Tablets AZATHIOPRINE **HOMECARE** 100mg in 5ml Suspension AZATHIOPRINE **HOMECARE** 25 mg Tablets AZATHIOPRINE **HOMECARE** 50 mg Tablets BETAMETHASONE VALERATE **HOMECARE** 0.1 % Cream BETAMETHASONE VALERATE **HOMECARE** 0.1 % Scalp Application BEZAFIBRATE **HOMECARE** 400 mg Modified Release Tablets CERTOLIZUMAB PEGOL **HOMECARE DELIVERY** 200 mg Pre-Filled Syringe CETIRIZINE **HOMECARE** 10 mg Tablets CHLORPHENAMINE **HOMECARE** 4 mg Tablets CICLOSPORIN (NEORAL) **HOMECARE** 10 mg Capsules CICLOSPORIN (NEORAL) **HOMECARE** 100 mg Capsules CICLOSPORIN (NEORAL) **HOMECARE** 100 mg in 1mL Oral Solution CICLOSPORIN (NEORAL) **HOMECARE** 25 mg Capsules CICLOSPORIN (NEORAL) **HOMECARE** 50 mg Capsules CLOBETASOL PROPIONATE **HOMECARE** 0.05 % Cream CLOTRIMAZOLE **HOMECARE** 1 % Cream CLOTRIMAZOLE HC **HOMECARE** 1 % Cream CODEINE PHOSPHATE **HOMECARE** 30 mg Tablets COLECALCIFEROL (HOMECARE) 20 micrograms (800 units) Capsules COLISTIMETHATE SODIUM **HOMECARE** (PROMIXIN) 1 mega unit Powder COLISTIMETHATE SODIUM **HOMECARE** (PROMIXIN) 1 mega unit Powder For Nebuliser Solution COLISTIMETHATE SODIUM **HOMECARE** 1 mega unit Injection CO-TRIMOXAZOLE **HOMECARE** 480 mg Tablets DAPSONE **HOMECARE** 50 mg Tablets DAPTOMYCIN **HOMECARE** 500 mg Injection DARUNAVIR **HOMECARE** 400 mg Tablets DARUNAVIR **HOMECARE** 600 mg Tablets DARUNAVIR **HOMECARE** 800 mg Tablets DIDANOSINE ** HOMECARE ** 250 mg Enteric Coated Capsules DIDANOSINE ** HOMECARE ** 400 mg Enteric Coated Capsules DIPROBASE **HOMECARE** Cream DOMPERIDONE **HOMECARE** 10 mg Tablets DORNASE ALFA (PULMOZYME) **HOMECARE** 2.5 mg Nebules DUODOPA CASSETTE **HOMECARE**

4 DUODOPA INITIATION KIT **HOMECARE** E45 **HOMECARE** Cream EFAVIRENZ **HOMECARE** 600 mg Film Coated Tablets EMTRICITABINE ** HOMECARE ** 200 mg Capsules ERTAPENEM **HOMECARE** 1 g Infusion ETANERCEPT **HOMECARE DELIVERY** 25 mg Injection ETANERCEPT **HOMECARE DELIVERY** 25 mg Pre-Filled Syringe ETANERCEPT **HOMECARE DELIVERY** 50 mg Pre-Filled Pen - **MYCLIC** ETANERCEPT **HOMECARE DELIVERY** 50 mg Pre-Filled Syringe EVIPLERA **HOMECARE** Tablets FERROUS FUMARATE **HOMECARE** 210 mg Tablets FERROUS SULPHATE **HOMECARE** 200 mg Tablets FINGOLIMOD **HOMECARE** 500 micrograms Capsules FLUCONAZOLE ** HOMECARE ** 50 mg Capsules FOLIC ACID **HOMECARE** 5 mg Tablets FOSAMPRENAVIR **HOMECARE** 700 mg Tablets GLATIRAMER ACETATE **HOMECARE DELIVERY** 20 mg in 1mL Pre-Filled Syringe GLATIRAMER ACETATE **HOMECARE DELIVERY** 40 mg/ml Pre-Filled Syringe GOLIMUMAB (SIMPONI) **HOMECARE** 100 mg Pre-Filled Pen GOLIMUMAB (SIMPONI) **HOMECARE** 50 mg Pre-Filled Pen IBUPROFEN **HOMECARE** 400 mg Tablets INFLIXIMAB in 250ml SODIUM CHLORIDE 0.9% **HOMECARE** INFUSION BETA - 1a (AVONEX BIO-SET) **HOMECARE DELIVERY** 30micrograms (6 million units) BETA - 1a (AVONEX BIO-SET) **HOMECARE DELIVERY** 30micrograms (6 million units) BETA - 1a (AVONEX) **HOMECARE DELIVERY** 30micrograms (6 million units) Pre-Filled BETA - 1a (AVONEX) **HOMECARE DELIVERY** 30micrograms (6 million units) BETA - 1a (AVONEX) **HOMECARE DELIVERY** 60micrograms (12 million units) BETA - 1a (REBIF) **HOMECARE DELIVERY** 22 micrograms (6 million units) in 0.5mL BETA - 1a (REBIF) **HOMECARE DELIVERY** 22 micrograms (6 million units) Pen BETA - 1a (REBIF) **HOMECARE DELIVERY** 22 micrograms (6 million units) Pre-Filled BETA - 1a (REBIF) **HOMECARE DELIVERY** 44 micrograms (12 million unis) Pen BETA - 1a (REBIF) **HOMECARE DELIVERY** 44 micrograms (12 million unis) Pre-Filled BETA - 1a (REBIF) **HOMECARE DELIVERY** 44 micrograms (12 million units) in 0.5m BETA - 1a (REBIF) **HOMECARE DELIVERY** Starter Pack Cartridge BETA - 1a (REBIF) **HOMECARE DELIVERY** Starter Pack Pen BETA - 1a (REBIF) **HOMECARE DELIVERY** Starter Pack Pre-Filled Syringe BETA-1b (BETAFERON) **HOMECARE DELIVERY** 300 micrograms (9.6 million units) BETA-1b (EXTAVIA) **HOMECARE DELIVERY** 300 micrograms (9.6 million units) Injection KALETRA **HOMECARE** (Lopinavir 200 mg & Ritonavir 50 mg) Tablets LAMIVUDINE 150mg & ZIDOVUDINE 300mg **HOMECARE** Tablets LISINOPRIL ** HOMECARE** 5 mg Tablets LOPERAMIDE **HOMECARE** 2 mg Capsules METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 10mg in 0.2ml Pre-Filled Pen METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 10mg in 0.2ml Pre-Filled Syringe METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 12.5mg in 0.25ml Pre-Filled Pen METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 15mg in 0.3ml Pre-Filled Pen

5 METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 15mg in 0.3ml Pre-Filled Syringe METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 20mg in 0.4ml Pre-Filled Pen METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 20mg in 0.4ml Pre-Filled Syringe METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 25mg in 0.5ml Pre-Filled Pen METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 25mg in 0.5ml Pre-Filled Syringe METHOTREXATE "HOMECARE DELIVERY ONLY" (Metoject) 7.5mg in 0.15ml Pre-Filled Pen METHOTREXATE **HOMECARE** 10 mg / 1mL (25mg in 2.5mL) Syrup METHOTREXATE **HOMECARE** 10 mg Tablets MULTIVITAMINS **HOMECARE** Tablets MYCOPHENOLATE MOFETIL (CELLCEPT) **HOMECARE** 1 g in 5mL Suspension MYCOPHENOLATE MOFETIL (CELLCEPT) **HOMECARE** 250 mg Capsules MYCOPHENOLATE MOFETIL (CELLCEPT) **HOMECARE** 500 mg Tablets MYCOPHENOLATE MOFETIL (MYFENAX) *HOMECARE* 250 mg Capsules MYCOPHENOLATE MOFETIL (MYFENAX) *HOMECARE* 500 mg Tablets MYCOPHENOLATE MOFETIL **HOMECARE** 250 mg Capsules MYCOPHENOLATE MOFETIL **HOMECARE** 500 mg Tablets MYCOPHENOLIC ACID (MYFORTIC) **HOMECARE** 180 mg Enteric Coated Tablets MYCOPHENOLIC ACID (MYFORTIC) **HOMECARE** 360 mg Enteric Coated Tablets NAPROXEN ** HOMECARE ** 500 mg Tablets NEVIRAPINE **HOMECARE** 200 mg Tablets NEVIRAPINE **HOMECARE** 400 mg Modified Release Tablets NURSE CHARGE *HOMECARE* PARACETAMOL **HOMECARE** 500 mg Tablets PRAVASTATIN **HOMECARE** 20 mg Tablets PRAVASTATIN **HOMECARE** 40 mg Tablets PREDNISOLONE **HOMECARE** 1 mg Tablets PREDNISOLONE **HOMECARE** 2.5 mg Enteric Coated Tablets PREDNISOLONE **HOMECARE** 25 mg Tablets PREDNISOLONE **HOMECARE** 5 mg Enteric Coated Tablets PREDNISOLONE **HOMECARE** 5 mg Soluble Tablets PREDNISOLONE **HOMECARE** 5 mg Tablets RALTEGRAVIR **HOMECARE** 400 mg Tablets RILPIVIRINE **HOMECARE** 25 mg Tablets RITONAVIR ** HOMECARE** 100 mg Tablets SIROLIMUS **HOMECARE** 1 mg in 1mL Oral Solution SIROLIMUS **HOMECARE** 1 mg Tablets SIROLIMUS **HOMECARE** 2 mg Tablets SIROLIMUS **HOMECARE** 500 micrograms Tablets SODIUM CHLORIDE **HOMECARE DELIVERY ONLY** 7 % Nebuliser Solution SOMATROPIN (GENOTROPIN MINI QUICK) **HOMECARE DELIVERY** 0.2 mg ( 0.6 units) Injection SOMATROPIN (GENOTROPIN MINI QUICK) **HOMECARE DELIVERY** 400 micrograms Injection SOMATROPIN (GENOTROPIN) **HOMECARE DELIVERY** 5.3mg (16 units) Cartridge SOMATROPIN (GENOTROPIN) **HOMECARE** 12mg (36 units) Injection SOMATROPIN (HUMATROPE) ** HOMECARE DELIVERY ONLY** 12mg (36 units) Cartridge SOMATROPIN (HUMATROPE) ** HOMECARE DELIVERY ONLY** 6mg (18 units) Cartridge SOMATROPIN (NORDITROPIN SIMPLEXx) **HOMECARE** 5 mg / 1.5mL Injection

6 SOMATROPIN (NUTROPIN AQ) ** HOMECARE DELIVERY** 10 mg in 2mL Cartridge SOMATROPIN (OMNITROPE) ** HOMECARE DELIVERY ONLY** 10mg (30 units) in 1.5mL Cartridge SOMATROPIN (OMNITROPE) ** HOMECARE DELIVERY ONLY** 5mg (15 units) in 1.5mL Cartridge SOMATROPIN (SAIZEN CLICK EASY) ** HOMECARE DELIVERY ONLY ** 8mg (24 units) Injection SOMATROPIN (SAIZEN) ** HOMECARE DELIVERY ONLY ** 12mg (36 units) Injection TACROLIMUS (ADOPORT) **HOMECARE** 1 mg Capsules TACROLIMUS (ADOPORT) **HOMECARE** 5 mg Capsules TACROLIMUS (ADOPORT) **HOMECARE** 500 micrograms Capsules TACROLIMUS (ADVAGRAF) **HOMECARE** 1 mg Modified Release Capsules TACROLIMUS (ADVAGRAF) **HOMECARE** 3 mg Modified Release Capsules TACROLIMUS (ADVAGRAF) **HOMECARE** 5 mg Modified Release Capsules TACROLIMUS (ADVAGRAF) **HOMECARE** 500 micrograms Modified Release Capsules TACROLIMUS (PROGRAF) **HOMECARE** 1 mg Capsules TACROLIMUS (PROGRAF) **HOMECARE** 5 mg Capsules TACROLIMUS (PROGRAF) **HOMECARE** 500 micrograms Capsules TEICOPLANIN REGIME *HOMECARE* 400 mg TEMAZEPAM **HOMECARE** 10 mg Tablets TENOFOVIR **HOMECARE** 245 mg Tablets TERIPARATIDE (FORSTEO) *** HOMECARE DELIVERY ONLY *** 20 micrograms per dose 3ml Pre-filled Pen TOBRAMYCIN (BRAMITOB) **HEALTHCARE AT HOME** 300 mg in 4mL Nebuliser Solution TRUVADA **HOMECARE** Tablets USTEKINUMAB (STELARA) **HOMECARE** 45 mg in 0.5mL Pre-Filled Syringe ZIDOVUDINE **HOMECARE** 100 mg Capsules ZIDOVUDINE **HOMECARE** 250 mg Capsules ZOPICLONE **HOMECARE** 3.75 mg Tablets d. How many patients are treated with the drug by this provider each year - This would take longer than 18 hours to determine this level of data and, therefore, pursuant of Section 12 of the Freedom of Information Act (Cost of compliance exceeds the appropraiate limit of 450, which equates to one person spending 18 hours in determining whether the Trust holds the information, locating, reviewing and extracting the data. We are, therefore, not obliged to process this matter further. e. For each of the above, please indicate the spend per-provider per-drug in each year - We are unable to provide this information under Section 43 of the Freedom of Information Act (Commercially sensitive information). *************************************************************************************************************** If you should have any further queries with regard to this matter please contact me at the above address. Please remember to quote the reference number above in any future communication. Please note that the information provided is the property of Derby Teaching Hospitals NHS Foundation Trust and subject to Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations This means that if you wish to re-use the information

7 provided for commercial purposes for any reason you must ask us for permission to do so. Should we agree that you can use the information it will be subject to the issue of a licence which may or may not involve a fee. If you have any questions about this process please contact us at dhft.foi@nhs.net. If you are unhappy with the service you have received in relation to this request and wish to make a complaint or request a review of our decision, you should write to: The Chief Executive Derby Teaching Hospitals NHS Foundation Trust The Royal Derby Hospital Uttoxeter Road Derby DE22 3NE If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision. Generally, the Information Commissioner s Office cannot make a decision unless you have exhausted the complaints procedure provided by this Trust. The Information Commissioner can be contacted at: The Information Commissioner s Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF Yours sincerely Jane Haywood Freedom of Information Officer

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and 5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

10 Musculoskeletal and Joint Diseases

10 Musculoskeletal and Joint Diseases 10 Musculoskeletal and Joint Diseases To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and British Society of Rheumatology guidelines and guidance

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016 To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical

More information

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active

More information

You requested information regarding the diagnostic imaging provision. Specifically you asked:

You requested information regarding the diagnostic imaging provision. Specifically you asked: Executive Corridor Memorial Hospital Switchboard Tel: 01325 38 0100 Foundation Trust Office: 01325 74 3625 Corporate Records Office: 01325 74 3700 Request for Information Reference: 10.16.08 Direct line:

More information

What does the HIV Pharmacy Team need to know about PEP

What does the HIV Pharmacy Team need to know about PEP What does the HIV Pharmacy Team need to know about PEP Rosy Weston Senior Lead Pharmacist Sexual Health and HIV St. Mary s Hospital Imperial College Healthcare NHS Trust London November 2008 Objectives

More information

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines

More information

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions

More information

Medications to Reduce the Risk of HIV Infection

Medications to Reduce the Risk of HIV Infection Medications to Reduce the Risk of HIV Infection INFORMATION ABOUT EARLY DRUG TREATMENT AFTER CONTACT WITH BLOOD OR BODY FLUIDS AUGUST 2018 THERE ARE MEDICATIONS (medicines) that you should take soon after

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

Lisa Evans. 9 May Freedom of Information Request Ref: FOI

Lisa Evans. 9 May Freedom of Information Request Ref: FOI Trust HQ Rikenel Montpellier Gloucester GL1 1LY Direct Tel: 01452 894266 E-mail: 2gnft.Information-Freedom@nhs.net Website: www.2gether.nhs.uk 9 May 2018 Freedom of Information Request Ref: FOI 038-1819

More information

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in

More information

Chapter 5 ~ Infections

Chapter 5 ~ Infections Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy

More information

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

5 December 2016 Our Ref: RFI Freedom of Information Act 2000 Provision of Services for Attention Deficit Hyperactivity Disorder (ADHD)

5 December 2016 Our Ref: RFI Freedom of Information Act 2000 Provision of Services for Attention Deficit Hyperactivity Disorder (ADHD) Information Governance 5 December 2016 Our Ref: RFI 18852 Dear Freedom of Information Act 2000 Provision of Services for Attention Deficit Hyperactivity Disorder (ADHD) I am writing to confirm that the

More information

Industry Data Request

Industry Data Request Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,

More information

Generic and originator immunosuppressants - comparative list prices and bioequivalence data

Generic and originator immunosuppressants - comparative list prices and bioequivalence data Ciclosporin Neoral (Novartis) Capimune (Mylan) NHS Net price (as per the BNF) Date: November 2016 Bioequivalence assessment vs. originator 10mg capsule, 60= 18.25 25mg capsule, 30= 18.37 50mg capsule,

More information

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not

More information

Your Ref: VY March Dear. Your Request for Information

Your Ref: VY March Dear. Your Request for Information Your Ref: VY 207 31 March 2014 NHS Vale of York CCG c/o North Yorkshire and Humber CSU Health House Grange Park Lane Willerby East Yorkshire HU10 6DT Telephone: (01482) 672191 Dear E-mail: VoYCCG.FOI@nhs.net

More information

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases

Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300

More information

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Date: 13 November Our Ref: FOI Dear Requester

Date: 13 November Our Ref: FOI Dear Requester Date: November 205 Chelsea and Westminster Hospital Information Governance Team Chelsea Harbour Harbour Yard Unit, st Floor London SW0 0XD www.chelwest.nhs.uk Our Ref: FOI 205-9 Dear Requester Thank you

More information

Thank you for your requests under the Freedom of Information Act Please find below responses to your questions.

Thank you for your requests under the Freedom of Information Act Please find below responses to your questions. Our reference: FOI/12-332 Dear Ms Mallinson Thank you for your requests under the Freedom of Information Act 2000. Please find below responses to your questions. 1. Please e-mail copies of the minutes

More information

Antiretrovial Crushable/Liquid Formulation Chart

Antiretrovial Crushable/Liquid Formulation Chart Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in

More information

PACK SIZE. 250mg 6 Take ONE capsule TWICE a day. D. Take 1 tablet FIVE times a day for 5 days as directed. 400mg 56 Take 1 tablet TWICE a day.

PACK SIZE. 250mg 6 Take ONE capsule TWICE a day. D. Take 1 tablet FIVE times a day for 5 days as directed. 400mg 56 Take 1 tablet TWICE a day. COES ORIGINL PCK? PROUCT NME N FORM PCK LBELLING INSTRUCTIONS MN514W 5055223604752 ESS661E 5055223600006 ESS514G 5055223600013 ESS028C 5055223600020 ESS500U 5055223600044 cetazolamide M/R ciclovir (dispersible)

More information

Advance Notification of Amendments to the June 2018 Drug Tariff

Advance Notification of Amendments to the June 2018 Drug Tariff Advance Notification of Amendments to the June 2018 Drug Tariff ADDITIONS Zero Discount Tacrolimus 1mg modified-release capsules Part I - Drugs And Preparations Special Container * This pack only (others

More information

Category and Product-level Procurement and Delivery Planning Guide

Category and Product-level Procurement and Delivery Planning Guide Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global

More information

RHEUMATOID ARTHRITIS DRUGS

RHEUMATOID ARTHRITIS DRUGS Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra

More information

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M % June 2016 On 13th May, the DH announced that there would be reductions to Category M prices from June until September. http://psnc.org.uk/our-news/contractor-notice-category-m-price-reduction/ This has

More information

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel

More information

UPLB-S , SUPPLY AND DELIVERY OF DRUGS AND MEDICINES TECHNICAL SPECIFICATION FOR THE PUBLIC BIDDING OF: OPENING OF BIDS:

UPLB-S , SUPPLY AND DELIVERY OF DRUGS AND MEDICINES TECHNICAL SPECIFICATION FOR THE PUBLIC BIDDING OF: OPENING OF BIDS: 1 1 0.3 Sodium Chloride with 5% Dextrose in 1000 ml in plastic bottle 2 0.3 Sodium Chloride With 5% Dextrose In 500 ml In Plastic Bottle 3 0.9 Sodium Chloride with 5% Dextrose 1000 ml in plastic bottle

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

FREEDOM OF INFORMATION DECISION NOTICE. FOI Reference Number: 870

FREEDOM OF INFORMATION DECISION NOTICE. FOI Reference Number: 870 Scarsdale Nightingale Close Newbold Chesterfield S41 7PF Tel.: 01246 514048 Date: 5 June 2018 FREEDOM OF INFORMATION DECISION NOTICE Dear Sir / Madam, FOI Reference Number: 870 I refer to your email of

More information

What is this leaflet about?

What is this leaflet about? Patient Information: Medicines Medicines commonly taken by people after a transplant or with an autoimmune disease Health & care information you can trust The Information Standard Certified Member Working

More information

SELF-ADMINISTERED MEDICATIONS LIST

SELF-ADMINISTERED MEDICATIONS LIST SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5

More information

Immunosuppressant medicines and your transplant

Immunosuppressant medicines and your transplant Immunosuppressant medicines and your transplant ESPRIT stands for Efficacy and Safety of PRescribing In Transplantation. As a multidisciplinary group, comprised of various relevant disciplines including

More information

FREEDOM OF INFORMATION ACT

FREEDOM OF INFORMATION ACT FOI REF: 19/165 22 March 2019 FREEDOM OF INFORMATION ACT I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows: Please

More information

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning

More information

Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date:

Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date: Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy

More information

DATE OF PRE-BID CONFERENCE: DEADLINE OF SUBMISSION OF BIDS: OPENING OF BIDS:

DATE OF PRE-BID CONFERENCE: DEADLINE OF SUBMISSION OF BIDS: OPENING OF BIDS: UHS FC: 8703417 Dr. Marilyn Reaño 1 1 0.3 Sodium Chloride with 5% Dextrose in 1000 ml in plastic 120 btl 70.00 8,400.00 2 0.3 Sodium Chloride With 5% Dextrose In 500 ml In Plastic 240 btl 70.00 16,800.00

More information

DT Description Price Category Price change

DT Description Price Category Price change Tariff T Watch October 2014 Readers are no doubt aware of this quarter's bad news for primary care prescribing allocations: NHS England has d the remuneration mechanism for community pharmacies gaining

More information

The Hospitalized HIV+ Patient

The Hospitalized HIV+ Patient The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential

More information

Cost impact of an HIV MDT for managing anti-retroviral switch

Cost impact of an HIV MDT for managing anti-retroviral switch Cost impact of an HIV MDT for managing anti-retroviral switch 2016 ST4 Farnaz Dave Infectious Diseases & General Internal Medicine Mr Ian Sayers Specialist Infectious Diseases Pharmacist Dr Fahar Niazi

More information

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY

SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09

More information

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz

Patient s perceptions of switching from Atripla to Truvada and generic efavirenz Patient s perceptions of switching from Atripla to Truvada and generic efavirenz Dr Hardeep Kang (ST4) Dr John Sweeney (Consultant) Background Atripla was approved as a fixed dose combination drug in 2006

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

LRI Children s Hospital

LRI Children s Hospital Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval

More information

Appropriate Use & Safety Edits

Appropriate Use & Safety Edits Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)

More information

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.

DRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection. `Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob

More information

Anti Infectives. Product Generic Name Dosage Form Strength Available Pack Sizes. Powder for Oral Suspension

Anti Infectives. Product Generic Name Dosage Form Strength Available Pack Sizes. Powder for Oral Suspension Product Disclaimer Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk. Product

More information

Paediatric antiretroviral therapy.

Paediatric antiretroviral therapy. Paediatric antiretroviral therapy. Guidelines exist for the choice of first line agents, but do not cover second line agents, other than recommending regimes of adequate potency. We would follow PENTA

More information

Compendium of Notified Ceiling Prices NLEM 2015

Compendium of Notified Ceiling Prices NLEM 2015 Compendium of Notified Ceiling Prices NLEM 2015 The Compendium of Notified Ceiling Prices of Scheduled Drugs as per NLEM 2015 has been brought out with the objective of disseminating information related

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Drug Treatment Program Update

Drug Treatment Program Update Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential

More information

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients

Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

FREEDOM OF INFORMATION ACT 2000 Dudley CCG - Growth Hormone Prescribing- Ref: RFI0222

FREEDOM OF INFORMATION ACT 2000 Dudley CCG - Growth Hormone Prescribing- Ref: RFI0222 Freedom of Information Team Dudley CCG Response by email 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU 27 th August 2015 FREEDOM OF INFORMATION ACT 2000 Dudley

More information

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017 To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea

More information

Industry Request Integrase Inhibitors

Industry Request Integrase Inhibitors Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/

More information

Suffolk Constabulary has considered your request for information and the response is below.

Suffolk Constabulary has considered your request for information and the response is below. Freedom of Information Request Reference N o : FOI 005896-17 I write in connection with your request for information received by Suffolk Constabulary on the 31 July 2017 in which you sought access to the

More information

2. What is the average cost of a cycle of an IVF cycle funded by the CCG and what does that include?

2. What is the average cost of a cycle of an IVF cycle funded by the CCG and what does that include? Communications & Engagement Team 1st Floor North Point Cardinal Square 10 Nottingham Road Derby DE1 3QT Tel: 01332 888080 Fax: 01332 868 898 www.southernderbyshireccg.nhs.uk Our ref: 340/16 Tuesday 26

More information

The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland

The Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents

More information

CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period

CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period There are currently no published guidelines for post-exposure prophylaxis from the CDC/PHS specific to the pediatric population. This

More information

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6 Abiraterone Tablet 250 mg Q4 2016 Acetylsalicylic Acid Tablet GR 100 mg Available Aciclovir Cream 5% - 2 Grs Available Alendronic Acid Tablet 70 mg Available Amikacin Solution for injection 50 mg/ml; 125mg/ml;

More information

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date

More information

Kern Pharma Portfolio 2014

Kern Pharma Portfolio 2014 Kern Pharma Portfolio 2014 DOSSIERS DEVELOPED DURING 2013-2014 ARIPIPRAZOL (ODT) 10mg, 15mg tablets CHONDROITIN SULPHATE 400mg capsules ( well established use ) DEXKETOPROFEN TROMETAMOL 25mg, tablets DULOXETIN

More information

20 June 2018 Our Ref: RFI 23569

20 June 2018 Our Ref: RFI 23569 Information Governance 20 June 2018 Our Ref: RFI 23569 Dear Freedom of Information Act 2000 Information in Relation to Translator Costs I am writing to confirm that the South Eastern Health & Social Care

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.

If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment. If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment. What is tacrolimus? Patient Information Drugs for Inflammatory Bowel Disease Tacrolimus

More information

SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC

SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC Supplementary Data SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC failure Envs (black dotted lines)

More information

Rajasthan Medical Services Corporation Limited, Jaipur

Rajasthan Medical Services Corporation Limited, Jaipur Rajasthan Medical Services Corporation Limited, Jaipur List of Drugs- Purchase order placed to successful Bidders Tendered on 05/07/2011 S.No. Name of Drug 1 Atropine Sulphate Injection 0.6 mg /ml (SC/IM/IV

More information

Area Drug and Therapeutics Committee Prescribing Supplement No 3 November 2003

Area Drug and Therapeutics Committee Prescribing Supplement No 3 November 2003 Area Drug and Therapeutics Committee Prescribing Supplement No 3 In this issue Drugs currently being considered by the SMC advice due on 8 December 2003. SMC Notice of meeting: Patient power Making a Difference,

More information

Mycophenolate Mofetil (MMF)

Mycophenolate Mofetil (MMF) SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code

More information

ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS

ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS ORAL ANTIRETROVIRAL ADMINISTRATION: INFORMATION ON CRUSHING AND LIQUID DRUG FORMULATIONS Combination Products: Atripla (efavirenz/ emtricitabine/ tenofovir) no Consider use of Truvada tabs and efavirenz

More information

Updates to the Alberta Human Services Drug Benefit Supplement

Updates to the Alberta Human Services Drug Benefit Supplement Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone

More information

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date: Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

More information

BNF 9: Blood and Nutrition

BNF 9: Blood and Nutrition FORMULARY CHOICE RESTRICTED 1 Blood and Blood-Forming Organs 1.1 Anaemias Epoetins Epoetinalfa pre-filled (Eprex ) 1,000unit 2,000unit 3,000unit 4,000unit 5,000unit 6,000unit 8,000unit 10,000unit 20,000unit

More information